Quantification of human angiogenesis in immunodeficient mice using a photon counting-based method

BioTechniques

Volumn 43, Issue 1, 2007, Pages 73-77

  Dong, Zhihong ^a   Neiva, Kathleen G ^a   Jin, Taocong ^a   Zhang, Zhaocheng ^a   Hall, Daniel E ^a   Mooney, David J ^b   Polverini, Peter J ^a   Nör, Jacques Eduardo ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; EXTRACELLULAR MATRICES; MURINE VASCULATURE;

BIOLUMINESCENCE; BLOOD VESSELS; CELL GROWTH; ENDOTHELIAL CELLS; HISTOLOGY; ONCOLOGY; PHOTONS;

DRUG PRODUCTS;

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PEG 300; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB;

ANALYTIC METHOD; ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MICROVASCULARIZATION; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; PHOTON; QUANTITATIVE ANALYSIS; REPRODUCIBILITY;

ANIMALS; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; LUMINESCENT MEASUREMENTS; MICE; MICE, SCID; NEOVASCULARIZATION, PHYSIOLOGIC; PHOTONS; REPRODUCIBILITY OF RESULTS; WHOLE BODY IMAGING;

ANIMALIA; MURINAE; MUS;

EID: 34447646320     PISSN: 07366205     EISSN: None     Source Type: Journal    
DOI: 10.2144/000112457     Document Type: Article

References (20)

1. Carmeliet, P. and P.K. Jain. 2000. Angiogenesis in cancer and other diseases. Nature 407:249-257.
2. Staton, C.A., S.M. Stribbling, S. Tazzyman, R. Hughes, N.J. Brown, and C.E. Lewis. 2004. Current methods for assaying angiogenesis in vitro and in vivo. Int. J. Exp. Pathol. 85:233-248.
3. Nör, J.E., M.C. Peters, J.B. Christensen, M.M. Sutorik, S. Linn, M.K. Khan, C.L. Addison, D.J. Mooney, and P.J. Polverini. 2001. Engineering and characterization of functional human microvessels in immunodeficient mice. Lab. Invest. 81:453-463.
4. Zeitlin, B.D., E. Joo, Z. Dong, K. Warner, G. Wang, Z. Nikolovska-Coleska, S. Wang, and J.E. Nör. 2006. Anti-angiogenic effect of TW37, a small molecule inhibitor of Bcl-2. Cancer Res. 66:8698-8706.
5. Contag, C.H. and B.D. Ross. 2002. It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J. Magn. Reson. Imaging 16:378-387.
6. Edinger, M., Y.A. Cao, Y.S. Hornig, D.E. Jenkins, M.R. Verneris, M.H. Bachmann, R.S. Negrin, and C.H. Contag. 2002. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur. J. Cancer 38:2128-2136.
7. Kang, S.H., H.T. Cho, S. Devi, Z. Zhang, D. Escuin, Z. Liang, H. Mao, D.J. Brat, et al. 2006. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res. 66:11991-11997.
8. Luo, J., A.H. Lin, E. Masliah, and T. Wyss-Coray. 2006. Bioluminescence imaging of Smad signaling in living mice shows correlation with excitotoxic neurodegeneration. Proc. Natl. Acad. Sci. USA 103:18326- 18331.
9. Yanagihara, K., M. Takigahira, F. Takeshita, T. Komatsu, K. Nishio, F. Hasegawa, and T. Ochiya. 2006. A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination. Cancer Res. 66:7532-7539.
10. Miller, A.D., D.G. Miller, J.V. Garcia, and C.M. Lynch. 1993. Use of retroviral vectors for gene transfer and expression. Met. Enzym. 217:581-599.
11. Pinsky, M.S., W. Song, Z. Dong, K. Warner, B. Zeitlin, E. Karl, D.E. Hall, and J.E. Nör. 2006. Activation of iCaspase-9 in neovessels inhibits oral tumor progression. J. Dent. Res. 85:436-441.
12. Nor, J.E., Y. Hu, W. Song, D.M. Spencer, and G. Nunez. 2002. Ablation of microvessels in vivo upon dimerization of iCaspase-9. Gene Ther. 9:444-451.
13. Song, W, Q. Sun, Z. Dong, D.M. Spencer, G. Nunez, and J.E. Nör. 2005. Anti-angiogenic gene therapy: disruption of neovascular networks mediated by inducible caspase-9 delivered with a transcriptionally targeted adenoviral vector. Gene Ther. 12:320-329.
14. Nör, J.E., J.B. Christensen, D.J. Mooney, and P.J. Polverini. 1999. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 154:375-384.
15. Lee, L., S. Sharma, B. Morgan, P. Allegrini, C. Schnell, J. Brueggen, R. Cozens, M. Horsfield, et al. 2006. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother. Pharmacol. 57:761-771.
16. Wood, J.M., G. Bold, E. Buchdunger, R. Cozens, S. Ferrari, J. Frei, F. Hofmann, J. Mestan, et al. 2000. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60:2178-2189.
17. Zakarija, A. and G. Soff. 2005. Update on angiogenesis inhibitors. Curr. Opin. Oncol. 17:578-583.
18. Yang, M., E. Baranov, X.M. Li, J.W. Wang, P. Jiang, L. Li, A.R. Moossa, S. Penman, and R.M. Hoffman. 2001. Whole body and intravital optical imaging of angiogenesis in orthotopically implanted tumors. Proc. Natl. Acad. Sci. USA 98:2616-2621.
19. Amoh, Y., M. Yang, L. Li, J. Reynoso, M. Bouvet, A.R. Moossa, K. Katsuoka, and R.M. Hoffman. 2005. Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis. Cancer Res. 65:5352-5357.
20. Doyle, T.C., S.M. Burns, and C.H. Contag. 2004. In vivo bioluminescence imaging for integrated studies of infection. Cell. Microbiol. 6:303-317.